MAPK8 and colorectal carcinoma: As shown in Figures 9(e)–9(i), after comprehensive conventional chemotherapy susceptibility analysis for the 138 kinds of chemotherapy drug, it was noted that gefitinib (P = 6.8e − 06), PLX4720 (P = 0.00046), AZD.2281 (P = 0.024), cisplatin (P =0.025), and JNK.inhibitor.VIII (P = 0.037) were more susceptible to the CRC patients in the high-risk group than in the low-risk group.